Source-grounded facts extracted from Tvardi Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tvardi Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP”
Tvardi Therapeutics, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.
“3,513,039 147,472 Cynthia Smith 3,392,877 267,634 Sujal Shah 3,507,652 152,859 Broker Non-Votes: 2,975,429 Proposal 2 – Non-Binding, Advisory Vote on Executive Compensation The stockholders approved,”
Tvardi Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Executive Compensation at the 2026-06-09 meeting.
“The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,482,265 161,795 16,451 2,975,429”
Tvardi Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.
“Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah were each elected to serve as a Class II director of the Company’s Board of Directors until the 2029 Annual Meeting of Stockholders”
Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $6.8 million, EPS $(0.73).
“Net loss for the three months ended March 31, 2026, was $6.8 million, as compared to a net loss of $9.6 million for the comparable period in 2025. Basic and diluted net loss per share attributable to common shareholders for the three months ended March 31, 2026, were a net loss of $(0.73), compared to a net loss of $(3.72) for the comparable period in 2025.”
Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.
“On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.”
Tvardi Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.
“On May 13, 2025, Deloitte was engaged as the Company’s independent registered public accounting firm”
Tvardi Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.
“ismissal of Independent Registered Public Accounting Firm On May 12, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective immediately”
Tvardi Therapeutics, Inc. underwent a change of control involving CT Convergence Merger Sub, Inc. (closed 2025-04-15).
“the Company reported, among other events, the completion of the Merger pursuant to which CT Convergence Merger Sub, Inc. merged with and into Tvardi Operating Company, Inc. (f/k/a Tvardi Therapeutics, Inc.)”
Tvardi Therapeutics, Inc.: As a result of the Merger, the Company ceased to be a shell company.
“As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.”
Tvardi Therapeutics, Inc.: Board approved and adopted a new Code of Business Conduct and Ethics that updated and enhanced the existing code with new policies on legal compliance, conflicts of interest, senior financial personnel conduct, respectful environment, asset protection, and media engagements (effective 2025-04-15).
“On April 15, 2025, the board of directors of the Company approved and adopted a new Code of Business Conduct and Ethics (the “Code”), which is applicable to all directors, officers, and employees of the Company.”
Tvardi Therapeutics, Inc. underwent a change of control involving Tvardi Therapeutics, Inc. (closed 2025-04-15).
“Cara changed its name from "Cara Therapeutics, Inc." to "Tvardi Therapeutics, Inc."”
Tvardi Therapeutics, Inc. completed a disposition involving CSL Vifor for $900,000 (closed 2025-04-15).
“rights for the development, manufacture and commercialization of difelikefalin as well as certain associated liabilities (the “Asset Disposition”) for a purchase price of $900,000 (subject to certain adjustments with respect to inventory). The Asset Disposition closed on April 15, 2025. 4 Pursuant to the APA, in connection with the consummation of the”
Tvardi Therapeutics, Inc. completed an acquisition involving Tvardi Therapeutics, Inc. (closed 2025-04-15).
“On April 15, 2025, Cara, Merger Sub and Tvardi consummated the transactions contemplated by the Merger Agreement”
Cynthia Smith was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Imran Alibhai, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Shaheen Wirk, M.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Wallace Hall was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Michael Wyzga was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Sujal Shah was appointed as Director and Chair of the Board at Tvardi Therapeutics, Inc..
“Sujal Shah was appointed to the Company’s board of directors and as Chair of our board of directors upon the closing of the Merger.”
Susan Shiff, Ph.D. was appointed as Director at Tvardi Therapeutics, Inc..
“the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.”
Lisa von Moltke, M.D. resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Jeffrey Ives, Ph.D. resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Helen M. Boudreau resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Christopher Posner resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Martin Vogelbaum resigned as Director at Tvardi Therapeutics, Inc..
“Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors”
Tvardi Therapeutics, Inc.: Amendment of Amended and Restated Certificate of Incorporation to effect a one-for-twelve reverse stock split and reduction in authorized shares from 200,000,000 to 16,666,667 (effective 2024-12-30).
“On December 30, 2024, Cara Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 (the “ Shares Reduction ”).”
Tvardi Therapeutics, Inc. announced a restructuring with charges of approximately $2.6 million (approximately 70%).
“On June 14, 2024, the Board of Directors of Cara Therapeutics, Inc. (the “Company”) approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after the Company announced its decision to discontinue the clinical program in notalgia paresthetica (“NP”) following the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP on June 12, 2024. In connection with the streamlined operating plan, the Board of Directors also approved a reduction in the Company’s workforce by approximately 70%, which the Company expects to substantially complete by June 30, 2024. The Company anticipates recognizing approximately $2.6 million in total charges in connection with the reduction in force, which costs are expected to be substantially recognized in the second and third quarter of 2024.”
Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.
“or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue”
Joana Goncalves resigned as Chief Medical Officer at Tvardi Therapeutics, Inc..
“On March 19, 2024, Dr. Joana Goncalves, the Chief Medical Officer of Cara Therapeutics, Inc. (the “Company”), informed the Company of her intention to resign from her role effective April 16, 2024, to pursue another opportunity.”
Tvardi Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $3.0 million, net income $32.3 million, EPS $(0.59) per basic and diluted share.
“For the fourth quarter of 2023, net loss was $32.3 million, or $(0.59) per basic and diluted share, compared to net loss of $30.3 million, or $(0.56) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $3.0 million and $3.3 million for the three months ended December 31, 2023 and 2022, respectively.”
Tvardi Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 1, 2024, Cara Therapeutics, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 30, 2024, to regain compliance with the minimum bid price requirement. To regain com”
Tvardi Therapeutics, Inc. announced a restructuring with charges of between $2.5 million and $3 million (a reduction in the Company’s workforce).
“On January 17, 2024, in connection with a review of the company’s strategic priorities, the Board of Directors of Cara Therapeutics, Inc. (the “Company”) approved a strategic reprioritization to focus the Company’s resources on the Company’s late stage clinical program evaluating oral difelikefalin in pruritus associated with notalgia paresthetica, and approved the termination of the Company’s Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease, including the termination of the ongoing KICK 1 and KICK 2 clinical trials. In connection with the termination of the oral chronic kidney disease program, the Board of Directors also approved a reduction in the Company’s workforce, which the Company expects to substantially complete by January 31, 2024. The Company anticipates recognizing between $2.5 million and $3 million in total charges in the first quarter of 2024 in connection with the reduction in force.”
Tvardi Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $4.9 million, net income $28.0 million, or $(0.52) per basic and diluted share, EPS $(0.52) per basic and diluted share.
“For the third quarter of 2023, net loss was $28.0 million, or $(0.52) per basic and diluted share, compared to net loss of $23.2 million, or $(0.43) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $4.9 million and $10.8 million for the three months ended September 30, 2023 and 2022, respectively.”
Tvardi Therapeutics, Inc. entered into Purchase and Sale Agreement with HCRX Investments Holdco, L.P. and Healthcare Royalty Partners IV, L.P. (collectively, HCR) valued at up to $40 million (effective 2023-11-01).
“On November 1, 2023 (the " Closing Date "), Cara Therapeutics, Inc. (the " Company "), through its wholly-owned subsidiary Cara Royalty Sub, LLC, a Delaware limited liability company (" Royalty Sub "), entered into a Purchase and Sale Agreement (the " Purchase and Sale Agreement ") with HCRX Investments Holdco, L.P., a Delaware limited partnership (" HCRx "), and Healthcare Royalty Partners IV, L.P., a Delaware limited partnership (collectively with HCRx, " HCR ").”
Tvardi Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $6.9 million (total revenue), net income ($31.5 million) net loss, EPS ($0.58) per basic and diluted share.
“or $(0.58) per basic and diluted share, compared to net loss of $4.2 million, or $(0.08) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.9 million and $23.0 million for the three months ended June 30, 2023 and 2022, respectively. Revenue primarily consisted of: · $5.4 million and $8.0 million of collaborative revenue”
Helen M. Boudreau was appointed as member of the Board at Tvardi Therapeutics, Inc..
“On August 2, 2023, upon the recommendation of its nominating and corporate governance committee, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Helen M. Boudreau, M.B.A. to serve as a member of the Board effective immediately.”
Tvardi Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“Proposal 3 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 43,767,233 179,748 66,965 –”
Tvardi Therapeutics, Inc. shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2023-06-01 meeting.
“Proposal 2 – Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 26,928,795 7,711,887 71,219 9,302,045”
Tvardi Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-01 meeting.
“Proposal 1 – Election of Directors Mr. Martin Vogelbaum and Dr. Lisa von Moltke were each elected to serve as a director of the Company’s Board of Directors until the 2026 Annual Meeting of Stockholders and until their successor is duly elected or until their earlier resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Martin Vogelbaum 28,082,224 6,629,677 9,302,045 Lisa von Moltke, M.D. 32,087,634 2,624,267 9,302,045”
Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $6.2 million, net income $26.7 million, EPS $(0.49) per basic and diluted share.
“For the first quarter of 2023, net loss was $26.7 million, or $(0.49) per basic and diluted share, compared to net loss of $27.7 million, or ($0.52) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.2 million and $4.8 million for the three months ended March 31, 2023 and 2022, respectively.”
Tvardi Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“On March 6, 2023, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.”
Tvardi Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $16.2M.
“Cara Therapeutics Reports Third Quarter 2022 Financial Results – Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection”
Lisa von Moltke, M.D. was appointed as Director at Tvardi Therapeutics, Inc..
“On November 1, 2022, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Lisa von Moltke, M.D. to serve as a member of the Board”
Ryan Maynard was appointed as Chief Financial Officer at Tvardi Therapeutics, Inc..
“announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.”
Richard Makara was appointed as Interim Chief Financial Officer at Tvardi Therapeutics, Inc..
“Effective immediately following Mr. Reilly’s departure, Richard Makara, the Company’s Vice President, Head of Accounting & Controller, will assume Mr. Reilly’s responsibilities on an interim basis.”
Thomas Reilly resigned as Chief Financial Officer at Tvardi Therapeutics, Inc..
“On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. (the “Company”), gave notice of his resignation, effective on or about June 15, 2022, to pursue a new opportunity.”
Christopher Posner was appointed as President and CEO at Tvardi Therapeutics, Inc..
“the appointment of Christopher Posner, age 52, a current non-employee director of the Company, to serve as President and CEO of the Company, effective November 9, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.